TechMARK movers: Biocompatibles raises revenue guidance

News that Biocompatibles is trading profitably has made it one of the better performers in TechMARK. The medical technology developer says it expects to report a first half profit in 2010. Biocompatibles' 2010 revenues are expected to be between £31m and £34m up from the previously indicated range of £28-£32m. Full year profit guidance will be provided with the interims. There should be more than £25m in cash at the end of 2010. The oncology products are selling better than expected. Products in the licensing division are progressing as hoped. Triad tops the losers after it fell into loss at the operating level. The pre-tax loss increased from £40,000 to £613,000 as revenues fell from £32.8m to £27.2m. A reduction in admin expenses reduced the rise in loss. The IT services provider was hit by cancelled and postponed projects. Client spending remains uncertain. FTSE TechMARK - RisersFiltronic (FTC) 28.00p +8.74%Puricore (PURI) 8.75p +5.71%Torotrak (TRK) 19.00p +5.26%Biocompatibles International (BII) 252.00p +4.35%Sinclair Pharma (SPH) 26.50p +1.92%Vectura Group (VEC) 45.25p +1.69%Smith & Nephew (SN.) 663.50p +1.45%Intec Telecom Systems (ITL) 59.25p +1.28%ProStrakan (PSK) 70.00p +1.08%Electronic Data Processing (EDP) 47.00p +1.06%FTSE TechMARK - FallersTriad Group (TRD) 23.00p -8.00%Vislink (VLK) 18.25p -5.19%Emblaze (BLZ) 39.25p -4.27%BATM Advanced (BVC) 23.75p -4.04%Renovo Group (RNVO) 25.50p -3.77%Skyepharma (SKP) 34.00p -2.86%KCOM Group (KCOM) 49.75p -2.45%NXT (NTX) 10.75p -2.27%Innovation Group (TIG) 11.75p -2.08%GB Group (GBG) 26.00p -1.92%